Peptides 101

KPV: Three Amino Acids That May Hold a Key to Gut Inflammation

KPV is the three-amino acid tail of a hormone your body already uses to calm inflammation. What the research says about this small but scientifically interesting anti-inflammatory peptide.

Man in a kitchen eating a bowl of various beans and vegetables.

LEGAL & MEDICAL DISCLAIMER: The information provided on this page by PeptideMatch.io is intended solely for educational and informational purposes. It does not constitute, and should not be interpreted as, professional medical advice, diagnosis, or treatment. Always consult a licensed physician or qualified healthcare provider before beginning any peptide therapy or making changes to an existing treatment plan. PeptideMatch.io does not prescribe, dispense, or endorse any specific therapeutic protocol. Individual results may vary, and no outcomes are guaranteed.

What Is KPV?

Your body already makes a hormone called alpha-melanocyte-stimulating hormone (alpha-MSH) that helps keep inflammation in check. It is a 13-amino acid chain, and researchers have spent decades trying to understand which part of it actually does the work. The answer, at least in the gut, appears to be the last three amino acids on the chain: lysine, proline, and valine.

KPV is a synthetic anti-inflammatory peptide built from those three amino acids. It is not found in food or produced independently by the body in meaningful amounts. What makes it scientifically interesting is not just what it does, but how it gets there. KPV is small enough to be absorbed through the gut wall using the same transporter system the body uses to absorb tripeptides from digested food, a route most peptide compounds cannot take.¹

KPV is currently an investigational compound. It does not have FDA approval for any indication, and the majority of the research to date has been conducted in cell cultures and animal models of inflammatory bowel disease (IBD).

Fast Facts

FULL NAME	Lysine-Proline-Valine (KPV)
CLASS	Tripeptide (3 amino acids)
PRIMARY ACTION	Blocks inflammatory signaling pathways in gut tissue
RESEARCH	Intestinal inflammation, protection of intestinal lining, and anti-microbial properties for conditions like eczema and psoriasis
REGULATORY STATUS	Investigational; not FDA-approved for any indication

How Does KPV Work?

A cascade of signals drive inflammation in the gut. One of the most important is a protein called NF-kB, which acts like a master switch for inflammation. When NF-kB is turned on, cells produce a wave of inflammatory proteins called cytokines, including TNF-alpha, IL-6, and IL-1beta. These cytokines then recruit immune cells to the gut wall, which intensify the inflammatory response, and contribute to tissue damage in conditions like colitis.¹

1. Direct Inhibition of Inflammatory Signaling

KPV works primarily by blocking NF-kB from being activated. It also interferes with a second inflammatory pathway called MAP kinase signaling. Together, these two actions reduce the output of pro-inflammatory cytokines from gut lining cells and immune cells in the intestinal wall.¹

2. Targeted Absorption Through PepT1

What sets KPV apart from many other anti-inflammatory compounds is how it reaches the gut wall. PepT1 is a transporter protein that normally sits in the small intestine and absorbs small peptides from digested food. In healthy tissue, it is largely absent from the colon. But in inflamed gut tissue, PepT1 expression increases significantly. This means KPV may be preferentially absorbed in the parts of the gut that are most inflamed, providing a targeted route of delivery.^1,2

3. Melanocortin Receptor Activity

KPV also binds to melanocortin receptors (specifically MC1R) on immune cells, which provides a second mechanism for reducing inflammatory activity. This dual approach, blocking NF-kB directly while also engaging the melanocortin receptor pathway, is part of what makes the KPV peptide an active subject of inflammatory bowel disease research.³

What Does the Research Say?

The research on KPV is preclinical, meaning it has been conducted in cell cultures and animal models rather than in human clinical trials. That is an important distinction. The findings are scientifically meaningful and have driven continued interest in this anti-inflammatory peptide, but they do not constitute proof of effectiveness or safety in humans.

The Dalmasso 2008 study in Gastroenterology is the most cited foundational paper on KPV. It was the first to demonstrate both the PepT1 uptake mechanism and the NF-kB blocking effect in the same study, and it showed that these effects occurred at very low concentrations. The Xiao 2017 Molecular Therapy study used a more advanced delivery system (hyaluronic acid-functionalized nanoparticles) to deliver KPV directly to inflamed colon tissue in animal models, and reported reductions in inflammation along with markers consistent with mucosal healing.^1,2

The primary area of research interest for the KPV peptide is inflammatory bowel disease, specifically ulcerative colitis and Crohn’s disease. These are conditions where the immune system attacks the lining of the gut, causing chronic inflammation, tissue damage, and symptoms like pain, bleeding, and difficulty absorbing nutrients. PeptideMatch.io presents this data so our community can understand what the science currently shows and where the research stands. KPV’s appeal in this context is its specificity. Rather than broadly suppressing immune activity, it targets specific inflammatory signaling pathways at the gut wall. The preclinical research points to several areas of interest:

THERAPEUTIC AREA	WHAT RESEARCH SUGGESTS	EVIDENCE LEVEL
Reduced Colitis Severity	In animal models of ulcerative colitis, oral KPV was associated with measurable reductions in inflammation markers and tissue damage scores compared to untreated controls.¹	Preclinical
Targeted Absorption	Because PepT1 expression increases in inflamed colon tissue, KPV may be absorbed more efficiently in the areas that need it most, rather than being distributed throughout the body.¹	Preclinical
Mucosal Healing Signals	The nanoparticle delivery research found markers associated with mucosal healing in treated animals, suggesting KPV may support the repair of the gut lining in addition to reducing inflammation.²	Preclinical
Dual Pathway Activity	KPV appears to work through both direct NF-kB inhibition and melanocortin receptor signaling, which may make it harder for the gut to develop resistance compared to single-pathway approaches.³	Preclinical

It is important to note that none of these findings has been replicated in human clinical trials. The translation from animal models to human outcomes in IBD research has historically been challenging, and KPV is no exception. The research is promising enough to warrant continued investigation, but not robust enough to support clinical recommendations.

Safety Profile

Because KPV has not been studied in human clinical trials, there is no established human safety profile. The preclinical research has not reported significant toxicity at the concentrations used in the animal studies, and the compound’s small size and natural origin from alpha-MSH suggest a low likelihood of severe adverse effects, but that is an inference from research data rather than evidence of human safety.

Important Considerations

No Human Trial Data	KPV has not been studied in human clinical trials. Safety and tolerability in people are not established.
Investigational Status	KPV is not FDA-approved for any condition. It is an investigational compound used in research settings.
Immune Modulation	Any compound that affects NF-kB signaling has the potential to influence immune function broadly. The full scope of KPV’s effects on the immune system in humans is not known.
No Established Dosing	There is no established safe or effective dose for humans. Dosing information from animal studies does not translate directly to human use.
Medical Oversight	Always work with a licensed healthcare provider before considering peptide therapy.

The Bottom Line: The preclinical research behind KPV is genuinely interesting. Because it works in more than one way, quieting inflammation, absorbing directly through an inflamed gut lining, and interacting with immune-regulating receptors, researchers are actively studying it as a potential treatment for inflammatory bowel disease.
What the research does not yet show is how any of this translates to humans. There are no human clinical trials, no established dosing, and no confirmed safety profile in people. The gap between a promising animal study and a proven human therapy is wide, and KPV has not yet crossed it. Anyone considering this compound should do so with the understanding that it is investigational, and should only be used under the supervision of a qualified healthcare provider.

Scientific References

Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.
Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Molecular Therapy. 2017;25(7):1628-1640.
Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324-331.

©2026 PeptideMatch.io. All Rights Reserved. This educational content is the exclusive intellectual property of PeptideMatch.io. Reproduction, distribution, republication, or transmission of this material, in whole or in part, in any form or by any means, is strictly prohibited without the prior written consent of PeptideMatch.io. For licensing or reprint inquiries, please contact content@peptidematch.io.